Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2137
Abstract: Patritumab deruxtecan is an antibody–drug conjugate consisting of a fully human monoclonal antibody against human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a tetrapeptide‐based cleavable linker. As part… read more here.
Keywords: clearance; patritumab deruxtecan; dxd; population pharmacokinetics ... See more keywords
Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-21-1429
Abstract: HER3 is ubiquitously expressed in EGFR-mutant non-small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery, Jänne… read more here.
Keywords: patritumab deruxtecan; egfr tki; deruxtecan paving; tki resistant ... See more keywords